← All trials
NCT05374954
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 10, 2022
- Primary completion
- Oct 10, 2022
- Completion date
- Nov 10, 2023
- First posted
- May 16, 2022
- Last posted
- Jun 1, 2022
- Enrollment
- 4200
- Arms / groups
- 28 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Government of ChinaCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.